Cipla is set to acquire a 100% stake in Inzpera Healthsciences Ltd. for ₹110.65 Crore, aiming to enhance its pharmaceutical portfolio.
Information on the Target
Cipla Limited has announced its intent to acquire a 100% stake in Inzpera Healthsciences Ltd., marking a strategic move to enhance its portfolio. The total estimated value of the transaction is ₹110.65 Crore, which positions Inzpera as a wholly-owned subsidiary of Cipla. The cash deal is expected to have an enterprise value of ₹120 Crore, reflecting Cipla's commitment to expanding its influence within the healthcare sector.
Industry Overview in India
The pharmaceutical industry in India is one of the fastest-growing sectors in the country's economy, with robust domestic and international demand. India is recognized as the world’s largest supplier of generic medications, which significantly contributes to both the national economy and the healthcare sector worldwide. The growth prospects for this industry remain positive due to increasing healthcare needs and a favorable regulatory environment.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Moreover, the Indian government has emphasized its support for the pharmaceutical sector, implementing policies that encourage research and development. This has led to a surge in investments and innovative drug development
Similar Deals
Somerset Indus Capital Partners → Apex Hospitals
2025
3one4 Capital, 360 ONE Asset, Vertex Growth Fund, Vertex Ventures SE Asia & India → Kapiva
2023
Cipla
invested in
Inzpera Healthsciences Ltd.
in 2025
in a Other deal
Disclosed details
Transaction Size: $1M
Enterprise Value: $1M
Equity Value: $1M